Shionogi weighs future of FXS drug after double Phase III miss

Shionogi's zatolmilast demonstrated an efficacy signal in one FXS study in adults, but it missed its primary endpoints across the programme. While Zatolmilast demonstrated an efficacy signal in one study in adults, the drug missed its primary endpoints across the FXS programme. Shionogi is determining whether it will continue to develop zatolmilast in fragile X syndrome by continuing its open-label study and conducting further exploratory analysis on the results from the EXPERIENCE programme. Credit: Yuriy K / Shutterstock.com. Shionogi is mulling over the fate of its fragile X syndrome (FXS) therapy, zatolmilast, after the drug failed to meet its primary…

Source: Clinical Trials Arena